FDA Awards Priority Review Voucher to Prometic Bioproduction, Inc. for Rare Pediatric Disease Product RYPLAZIM

Summary

The FDA is issuing a priority review voucher to Prometic Bioproduction, Inc. for its rare pediatric disease product application, RYPLAZIM, which meets the required criteria under the Federal Food, Drug, and Cosmetic Act.